LGALS3 and prostate carcinoma: Taken together, these results demonstrated that the levels and the cellular location of the Galectin-3 vary during prostate cancer progession, since the malignant transformation of prostate cells is associated with cellular redistribution of the Galectin-3 and a decrease in tissue levels of this protein (57).